Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.59) by 76.27 percent. This is a 126.09 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $50.529 million which missed the analyst consensus estimate of $61.925 million by 18.40 percent. This is a 3.92 percent decrease over sales of $52.590 million the same period last year.